Statement of Changes in Beneficial Ownership (4)

FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Brown Bob D	2. Issuer Name and Ticker or Trading Symbol Dicerna Pharmaceuticals Inc [ DRNA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Scientific Ofr., EVP R&D
(Last) (First) (Middle) C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE	3. Date of Earliest Transaction (MM/DD/YYYY) 12/28/2021
(Street) LEXINGTON, MA 02421 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/28/2021		U⁽¹⁾		2367 ⁽¹⁾	D	$38.25 ⁽¹⁾	0	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽²⁾	12/28/2021		D			25950	⁽³⁾	⁽³⁾	Common Stock	25950.0	⁽³⁾	0	D
Restricted Stock Units	⁽²⁾	12/28/2021		D			11325	⁽³⁾	⁽³⁾	Common Stock	11325.0	⁽³⁾	0	D
Employee Stock Option (Right to Buy)	$9.09	12/28/2021		D			85000	⁽⁴⁾	⁽⁴⁾	Common Stock	85000.0	⁽⁴⁾	0	D
Employee Stock Option (Right to Buy)	$9.3	12/28/2021		D			105000	⁽⁴⁾	⁽⁴⁾	Common Stock	105000.0	⁽⁴⁾	0	D
Employee Stock Option (Right to Buy)	$11.77	12/28/2021		D			180000	⁽⁴⁾	⁽⁴⁾	Common Stock	180000.0	⁽⁴⁾	0	D
Employee Stock Option (Right to Buy)	$16.3	12/28/2021		D			165050	⁽⁴⁾	⁽⁴⁾	Common Stock	165050.0	⁽⁴⁾	0	D
Employee Stock Option (Right to Buy)	$18.5	12/28/2021		D			75000	⁽⁴⁾	⁽⁴⁾	Common Stock	75000.0	⁽⁴⁾	0	D
Employee Stock Option (Right to Buy)	$22.58	12/28/2021		D			121300	⁽⁴⁾	⁽⁴⁾	Common Stock	121300.0	⁽⁴⁾	0	D
Employee Stock Option (Right to Buy)	$24.05	12/28/2021		D			68100	⁽⁴⁾	⁽⁴⁾	Common Stock	68100.0	⁽⁴⁾	0	D

Explanation of Responses:
(1)	This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
(2)	Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
(3)	At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).
(4)	Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Brown Bob D C/O DICERNA PHARMACEUTICALS, INC. 75 HAYDEN AVENUE LEXINGTON, MA 02421			Chief Scientific Ofr., EVP R&D